UCB's bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis
Brussels (ots/PRNewswire) - - Bimekizumab is a highly selective monoclonal antibody that inhibits the activity of both IL-17A and IL-17F, key pro-inflammatory cytokines expressed in several inflammatory diseases[1],[2] - In this early proof of concept study, bimekizumab showed fast and sustained efficacy on disease ...